Short Interest in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Expands By 102.0%

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) saw a large growth in short interest in December. As of December 15th, there was short interest totaling 27,450 shares, a growth of 102.0% from the November 30th total of 13,586 shares. Based on an average daily trading volume, of 25,799 shares, the days-to-cover ratio is currently 1.1 days. Approximately 0.0% of the company’s shares are sold short. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 25,799 shares, the days-to-cover ratio is currently 1.1 days.

Analyst Ratings Changes

Several research analysts have commented on the company. Wall Street Zen upgraded Pharming Group to a “strong-buy” rating in a report on Saturday. Zacks Research upgraded Pharming Group from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 6th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pharming Group in a report on Monday, December 22nd. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, Pharming Group presently has a consensus rating of “Buy” and an average price target of $38.00.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its holdings in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) by 8.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 52,147 shares of the company’s stock after buying an additional 4,150 shares during the quarter. Silverberg Bernstein Capital Management LLC owned about 0.08% of Pharming Group worth $557,000 at the end of the most recent quarter. 0.03% of the stock is owned by institutional investors and hedge funds.

Pharming Group Stock Performance

PHAR stock traded down $0.51 on Monday, hitting $17.30. The company’s stock had a trading volume of 44,827 shares, compared to its average volume of 10,315. The company has a current ratio of 3.16, a quick ratio of 2.39 and a debt-to-equity ratio of 0.35. Pharming Group has a 1 year low of $7.50 and a 1 year high of $18.30. The firm has a 50 day moving average of $15.96 and a two-hundred day moving average of $13.74. The stock has a market cap of $1.18 billion and a price-to-earnings ratio of -1,727.77.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.05. The company had revenue of $97.30 million during the quarter, compared to analysts’ expectations of $98.22 million. Pharming Group had a return on equity of 0.46% and a net margin of 0.30%. Equities analysts predict that Pharming Group will post -0.2 EPS for the current fiscal year.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.